Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
- Trusted Brand: Brought to you by Apex Energetics, a leader in the health and wellness industry
No one should consider the information on this platform as a substitute for professional medical advice, diagnosis or treatment
Get rid of your sugar cravings Unhealthy blood sugar levels can negatively impact many aspects of your health, including fatigue, disrupted sleep, unwanted cravings, stress, brain fog and even accelerated aging
Key Points Native human GLP-1 normalizes hyperglycaemia in patients with type 2 diabetes mellitus, but the short in vivo half-life of this hormone limits its therapeutic application A number of synthetic GLP-1 receptor agonists, with half-lives between 23 h and several days, have been developed for the long-term treatment of type 2 diabetes mellitus Short-acting GLP-1 receptor agonists (such as exenatide and lixisenatide) predominantly lower postprandial glucose levels and insulin concentrations via retardation of gastric emptying Long-acting GLP-1 receptor agonists (such as albiglutide, dulaglutide, exenatide long-acting release and liraglutide) predominantly lower blood glucose levels through stimulation of insulin secretion and reduction of glucagon levels Adverse effects of GLP-1 receptor agonists include nausea, vomiting and diarrhoea, injection-site reactions, antibody formation and increased heart rate This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
Not the mild, transient oxidative stress of caloric deficit and fat mobilisation during GLP-1 therapy
US$ 27.38
US$ 24.96
US$ 23.04
